| A fully human monoclonal antibody that selectively blocks the interaction of PD-L1 with its receptors, PD-1 and CD80 |
| Significantly prolongs overall survival when added to etoposide plus either carboplatin or cisplatin; benefits were sustained with longer follow-up |
| Manageable tolerability profile |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.